Black Diamond Therapeutics logo
Startup

Black Diamond Therapeutics

See Black Diamond Therapeutics's full profile

BOOK A DEMO
Headquarters

United States

Founded Year

2019

Total Funding

$197.1M

Employees

51 - 200

Status

Active


About Black Diamond Therapeutics

Black Diamond Therapeutics Inc. is a leading venture-backed biotechnology company focused on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes.

Headquarters

United States


General Information on Black Diamond Therapeutics

Brand name Black Diamond Therapeutics
Company name Black Diamond Therapeutics Inc.
Website https://www.blackdiamondtherapeutics.com/
Founded year 2019
Employees 51 - 200
Founding team

Alexander Mayweg

Contact [email protected]

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about Black Diamond Therapeutics

Market Screener 20.09.2022
Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from S&P Global BMI Index | MarketScreener

Black Diamond Therapeutics, Inc.(NasdaqGS:BDTX) dropped from SP Global BMI Index

Black Diamond Therapeutics news
Riverton Roll 07.09.2022
Elevation Oncology (NASDAQ:ELEV) & Black Diamond Therapeutics (NASDAQ:BDTX) Head-To-Head Analysis

Elevation Oncology ( NASDAQ:ELEV – Get Rating ) and Black Diamond Therapeutics ( NASDAQ:BDTX – Get Rating ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings. Analyst Recommendations This is a summary of recent recommendations for Elevation Oncology ...

Black Diamond Therapeutics news
PressOracle 07.09.2022
Analyzing Black Diamond Therapeutics (NASDAQ:BDTX) & Elevation Oncology (NASDAQ:ELEV)

Elevation Oncology ( NASDAQ:ELEV – Get Rating ) and Black Diamond Therapeutics ( NASDAQ:BDTX – Get Rating ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Insider & Institutional Ownership 74.0% of Elevation Oncology shares are held by ...

Black Diamond Therapeutics news
StreetInsider 07.09.2022
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

September 6, 2022 8:00 AM EDT CAMBRIDGE, Mass. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX ), a precision oncology medicine company pioneering the discovery and development of Master Key therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company's progress at the H.C. Wainwright th Annual Global Investment ...

Black Diamond Therapeutics news
BioTech and BioPharm News at BioSpace 07.09.2022
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences in September 2022

CAMBRIDGE, Mass. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Master Key therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be ...

ETF Daily News 13.08.2022
Q3 2022 Earnings Forecast for Black Diamond Therapeutics, Inc. Issued By Wedbush (NASDAQ:BDTX)

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Rating) – Stock analysts at Wedbush upped their Q3 2022 earnings estimates for Black Diamond Therapeutics in a research report issued on Wednesday, August 10th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.65) per share for the quarter, up from their prior forecast of ($0.70). The consensus estimate for Black Diamond Therapeutics’ current full-year ...

Black Diamond Therapeutics news
MarketBeat.com 12.08.2022
Q3 2022 EPS Estimates for Black Diamond Therapeutics, Inc. Raised by Analyst (NASDAQ:BDTX)

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Rating) - Research analysts at Wedbush boosted their Q3 2022 earnings per share (EPS) estimates for shares of Black Diamond Therapeutics in a note issued to investors on Wednesday, August 10th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($0.65) per share for the quarter, up from their prior forecast of ($0.70). The consensus estimate for Black Diamond ...

Black Diamond Therapeutics news
Modern Readers 11.08.2022
Black Diamond Therapeutics (NASDAQ:BDTX) Issues Earnings Results

Black Diamond Therapeutics (NASDAQ:BDTX – Get Rating) issued its earnings results on Tuesday. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.05, Fidelity Earnings reports. BDTX stock traded up $0.02 during trading on Thursday, reaching $3.95. 46,317 shares of the stock were exchanged, compared to its average volume of 177,450. The business has a 50 day moving average ...

Black Diamond Therapeutics news
Daily Political 11.08.2022
Black Diamond Therapeutics (NASDAQ:BDTX) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Black Diamond Therapeutics (NASDAQ:BDTX – Get Rating) announced its quarterly earnings data on Tuesday. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.05, Fidelity Earnings reports. Shares of NASDAQ BDTX traded up $0.02 on Thursday, reaching $3.95. 46,317 shares of the company traded hands, compared to its average volume of 177,450. Black Diamond Therapeutics has a fifty-two week low of ...

Black Diamond Therapeutics news
Stock Observer 10.08.2022
Black Diamond Therapeutics (NASDAQ:BDTX) Issues Quarterly Earnings Results

Black Diamond Therapeutics ( NASDAQ:BDTX – Get Rating ) released its quarterly earnings results on Tuesday. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.05, Fidelity Earnings reports. Black Diamond Therapeutics Stock Up 3.4 % BDTX traded up $0.13 during trading on Wednesday, hitting $3.92. 25,029 shares of the stock were exchanged, compared to its average volume of 388,867. The firm has a ...

Black Diamond Therapeutics news